DaVita HealthCare Partners Inc. (DVA) Given Consensus Rating of “Hold” by Brokerages
DaVita HealthCare Partners Inc. (NYSE:DVA) has been assigned a consensus recommendation of “Hold” from the seventeen analysts that are presently covering the stock. One investment analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $74.45.
Several analysts recently commented on the stock. JPMorgan Chase & Co. raised their price target on shares of DaVita HealthCare Partners from $74.00 to $75.00 and gave the company a “neutral” rating in a research report on Tuesday, August 9th. Raymond James Financial Inc. upgraded shares of DaVita HealthCare Partners from a “market perform” rating to an “outperform” rating and set a $75.00 price target on the stock in a research report on Tuesday, September 20th. Zacks Investment Research lowered shares of DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a research report on Wednesday, July 27th. SunTrust Banks Inc. set a $66.00 price target on shares of DaVita HealthCare Partners and gave the company a “hold” rating in a research report on Thursday, October 13th. Finally, Citigroup Inc. initiated coverage on shares of DaVita HealthCare Partners in a research report on Tuesday, September 6th. They set a “neutral” rating and a $71.00 price target on the stock.
In other DaVita HealthCare Partners news, COO Michael David Staffieri sold 20,262 shares of DaVita HealthCare Partners stock in a transaction dated Tuesday, August 9th. The shares were sold at an average price of $73.09, for a total transaction of $1,480,949.58. Following the transaction, the chief operating officer now directly owns 52,279 shares of the company’s stock, valued at $3,821,072.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.10% of the company’s stock.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/davita-healthcare-partners-inc-dva-given-consensus-rating-of-hold-by-brokerages.html
Institutional investors have recently modified their holdings of the company. Glenmede Trust Co. NA increased its position in shares of DaVita HealthCare Partners by 63.9% in the first quarter. Glenmede Trust Co. NA now owns 3,906 shares of the company’s stock worth $286,000 after buying an additional 1,523 shares during the period. ING Groep NV purchased a new position in shares of DaVita HealthCare Partners during the first quarter worth approximately $278,000. Aviva PLC increased its position in shares of DaVita HealthCare Partners by 1.1% in the first quarter. Aviva PLC now owns 108,300 shares of the company’s stock worth $7,947,000 after buying an additional 1,181 shares during the period. Credit Agricole S A increased its position in shares of DaVita HealthCare Partners by 8.7% in the first quarter. Credit Agricole S A now owns 81,202 shares of the company’s stock worth $5,958,000 after buying an additional 6,498 shares during the period. Finally, Canada Pension Plan Investment Board increased its position in shares of DaVita HealthCare Partners by 560.4% in the first quarter. Canada Pension Plan Investment Board now owns 51,796 shares of the company’s stock worth $3,801,000 after buying an additional 43,953 shares during the period. 83.54% of the stock is currently owned by institutional investors.
Shares of DaVita HealthCare Partners (NYSE:DVA) traded up 0.43% during mid-day trading on Wednesday, hitting $62.78. 727,852 shares of the stock traded hands. DaVita HealthCare Partners has a 12 month low of $61.36 and a 12 month high of $78.94. The company has a market cap of $12.99 billion, a P/E ratio of 36.52 and a beta of 0.96. The firm has a 50 day moving average of $64.35 and a 200 day moving average of $72.14.
DaVita HealthCare Partners (NYSE:DVA) last released its quarterly earnings results on Monday, August 8th. The company reported $1.01 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.98 by $0.03. The company had revenue of $3.72 billion for the quarter, compared to analyst estimates of $3.67 billion. DaVita HealthCare Partners had a net margin of 2.51% and a return on equity of 16.48%. The firm’s revenue was up 8.2% on a year-over-year basis. During the same quarter last year, the business earned $0.95 earnings per share. Equities analysts anticipate that DaVita HealthCare Partners will post $3.76 EPS for the current fiscal year.
About DaVita HealthCare Partners
DaVita HealthCare Partners Inc is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. Its segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives. Its Kidney Care division is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD).
Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.